• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Do beta-lactam-beta-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis?

作者信息

Yew W W, Wong C F, Lee J, Wong P C, Chau C H

出版信息

Tuber Lung Dis. 1995 Feb;76(1):90-2. doi: 10.1016/0962-8479(95)90588-x.

DOI:10.1016/0962-8479(95)90588-x
PMID:7718855
Abstract
摘要

相似文献

1
Do beta-lactam-beta-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis?
Tuber Lung Dis. 1995 Feb;76(1):90-2. doi: 10.1016/0962-8479(95)90588-x.
2
Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.阿莫西林-克拉维酸用于治疗耐药结核分枝杆菌。
Chest. 1991 Apr;99(4):1025-6. doi: 10.1378/chest.99.4.1025.
3
[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?].[牛分枝杆菌引起的多重耐药结核病与人类免疫缺陷病毒感染。是否有新的治疗可能性？]
Enferm Infecc Microbiol Clin. 2001 Jan;19(1):37-9.
4
[The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis].阿莫西林-克拉维酸与氧氟沙星联合治疗耐多药结核分枝杆菌
Kekkaku. 1997 Jan;72(1):9-13.
5
[A study of beta-lactamase activity of mycobacteria and clinical trial of penicillin/beta-lactamase inhibitor combinations in the treatment of drug-resistant Mycobacterium tuberculosis].
Kekkaku. 1999 May;74(5):447-52.
6
Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis.
Scand J Infect Dis. 2001;33(6):466-9. doi: 10.1080/00365540152029954.
7
In-vitro activity of augmentin against clinically important gram-positive and gram-negative bacteria in comparison with other antibiotics.
Zentralbl Bakteriol Mikrobiol Hyg A. 1984 Apr;256(4):523-30. doi: 10.1016/s0174-3031(84)80029-3.
8
The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.β-内酰胺类与β-内酰胺酶抑制剂对耐多药结核分枝杆菌临床菌株的体外疗效
Int J Antimicrob Agents. 2004 Apr;23(4):408-11. doi: 10.1016/j.ijantimicag.2003.09.023.
9
Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.使用β-内酰胺/β-内酰胺酶抑制剂组合作为抗分枝杆菌药物。
Microbios. 1993;76(309):251-61.
10
[Progress in chemotherapeutic agents--beta-lactam antibiotics and beta-lactamase inhibitors].[化疗药物的进展——β-内酰胺类抗生素与β-内酰胺酶抑制剂]
Nihon Rinsho. 1986 Apr;44(4):824-30.

引用本文的文献

1
Have we realized the full potential of β-lactams for treating drug-resistant TB?我们是否已经充分挖掘了β-内酰胺类药物治疗耐药性结核病的潜力？
IUBMB Life. 2018 Sep;70(9):881-888. doi: 10.1002/iub.1875. Epub 2018 Jun 22.
2
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.碳青霉烯类药物治疗多重耐药和广泛耐药结核病：一项系统评价。
Int J Mol Sci. 2016 Mar 12;17(3):373. doi: 10.3390/ijms17030373.
3
Reappraising the use of β-lactams to treat tuberculosis.重新评估β-内酰胺类药物治疗结核病的应用。
Expert Rev Anti Infect Ther. 2012 Sep;10(9):999-1006. doi: 10.1586/eri.12.96.
4
Current development and future prospects in chemotherapy of tuberculosis.结核病化疗的现状与展望。
Respirology. 2010 Jul;15(5):764-78. doi: 10.1111/j.1440-1843.2010.01775.x. Epub 2010 Jun 4.
5
Imipenem for treatment of tuberculosis in mice and humans.亚胺培南用于治疗小鼠和人类的结核病。
Antimicrob Agents Chemother. 2005 Jul;49(7):2816-21. doi: 10.1128/AAC.49.7.2816-2821.2005.
6
Treatment and prevention of multidrug-resistant tuberculosis.耐多药结核病的治疗与预防
Drugs. 1999 Oct;58(4):633-61. doi: 10.2165/00003495-199958040-00005.
7
Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis.结核分枝杆菌主要β-内酰胺酶的重组表达与特性分析
Antimicrob Agents Chemother. 1998 Jun;42(6):1375-81. doi: 10.1128/AAC.42.6.1375.
8
Future directions in the development of new antitubercular drugs. Where do we go from here?新型抗结核药物研发的未来方向。我们从这里走向何方？
Drugs Aging. 1997 Jun;10(6):405-10. doi: 10.2165/00002512-199710060-00001.
9
Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra.结核分枝杆菌H37Ra A类β-内酰胺酶的克隆与序列分析
Antimicrob Agents Chemother. 1997 May;41(5):1182-5. doi: 10.1128/AAC.41.5.1182.